Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05621759 · ClinicalTrials.gov registry record · Phase 2
Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD
A Phase 2 study of Graft Vs Host Disease, sponsored by NYU Langone Health.
- Active
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT05621759 is a Phase 2 study of Graft Vs Host Disease that is active but no longer recruiting, run by NYU Langone Health. The registered enrollment target is 27 participants, below the 137-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05621759, a Phase 2 study of Graft Vs Host Disease, is active but no longer recruiting, sponsored by NYU Langone Health.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single arm, open label, phase II clinical trial. Adult patients with hematological malignancies undergoing allogeneic HSCT from first- or second-degree haploidentical donor are eligible for the study if they meet the standard criteria defined in our institutional standard operation procedures (SOPs), meet all inclusion criteria, and do not satisfy any exclusion criteria. Patients will receive non-myeloablative, reduced-intensity or myeloablative conditioning regimen followed by peripheral blood hematopoietic stem cells. Patients will receive dosed reduced cyclophosphamide, abatacept, and short-duration tacrolimus for GvHD prophylaxis.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Abatacept
- DRUG Tacrolimus
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2022-09-07 |
| Est. Completion | 2027-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05621759
The ClinicalTrials.gov registry entry for NCT05621759 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 137-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (80% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Graft Vs Host Disease appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT05621759 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05621759 about?
NCT05621759 is a clinical study titled "Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD". This is a single arm, open label, phase II clinical trial. Adult patients with hematological malignancies undergoing allogeneic HSCT from first- or second-degree haploidentical donor are eligible for the study if they meet the standard criteria defined in our institutional standard operation procedu...
What is the current status of trial NCT05621759?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2022-09-07. Estimated completion is 2027-01-30.
What conditions does trial NCT05621759 study?
This clinical trial studies the following conditions: Graft Vs Host Disease.
What interventions are being tested in trial NCT05621759?
The interventions under investigation include: Cyclophosphamide (DRUG), Abatacept (DRUG), Tacrolimus (DRUG).
Who is sponsoring clinical trial NCT05621759?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05621759 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft Vs Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis
RECRUITING · Phase 2
-
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
RECRUITING · Phase 2
-
Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.
RECRUITING · Phase 2
-
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
ACTIVE NOT RECRUITING · Phase 2
-
RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation
COMPLETED · Phase 2
-
Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.